University of Minnesota Medical School

CHOP-led Study Shows that Antibiotic-Resistant Microbes in the Gut Make C. difficile More Infectious

Retrieved on: 
Wednesday, November 16, 2022
Health, Doctor of Philosophy, University of Minnesota Medical School, Philadelphia, Hospital, Clostridioides difficile infection, RNA, IBD, Infection, VRE, Prussia, University of Virginia, Environment, Collection, Metabolomics, Clostridioides difficile (bacteria), University, Vancomycin-resistant Enterococcus, Vanderbilt University School of Medicine, Assistant, Ornithine, Pathology, Research, Association, Organic acid, Patient, Nutrient, Inflammatory bowel disease, University of Florida, University of Pittsburgh, Children's Hospital of Philadelphia, DOI, Medical laboratory, Virulence, Arginine, Gastrointestinal tract, CHOP, Public health, Dietary supplement, Pharmaceutical industry, Nature, Child, Enterococcus

PHILADELPHIA, Nov. 16, 2022 /PRNewswire/ -- Clostridioides difficile, often referred to as C. difficile or C. diff, is a bacterium that causes severe intestinal illness and, as its name suggests, can be difficult to study and treat. Approximately 1 in 6 patients infected with C. difficile will be reinfected within two months. Yet scientists have not figured out why C. difficile infection is more difficult to treat in some patients versus others. The human gut is filled with trillions of microbes, and these microbes influence the virulence of various pathogens, but until now, scientists had little understanding of how C. difficile cooperates with the rich collection of microorganisms in the gastrointestinal tract.

Key Points: 
  • Yet scientists have not figured out why C. difficile infection is more difficult to treat in some patients versus others.
  • Prior studies have shown that adults infected with C. difficile also have high levels of Enterococcus in their gut and that vancomycin-resistant Enterococcus (VRE) frequently co-infects patients with C. difficile.
  • They also observed a positive correlation between C. difficile burdens and ornithine, supporting a key role for this amino acid in C. difficile infection.
  • difficile."

Katherine A. Daly, MD is recognized by Continental Who's Who

Retrieved on: 
Tuesday, November 15, 2022
Indian Medical Association, American Academy of Child and Adolescent Psychiatry, Medicine, Differential diagnosis, MD, Heart, Adolescence, American Board of Commissioners for Foreign Missions, Woman, M Health Fairview, American Medical Association, Dream, American Psychiatric Association, Pediatrics, Panic disorder, University, Physician, American, Loyola, Psychiatry, Love, Neurology, American Board of Pediatrics, American Board of Psychiatry and Neurology, University of Minnesota Medical School, American Academy, Trinity Health (Livonia, Michigan), Continental, Epilepsy, Child

WAYZATA, Minn., Nov. 15, 2022 /PRNewswire/ -- Katherine A. Daly, MD, is being recognized by Continental Who's Who as a Trusted Healthcare Professional in the Medical field, acknowledging her exemplary work with Fairview Health Services.

Key Points: 
  • WAYZATA, Minn., Nov. 15, 2022 /PRNewswire/ -- Katherine A. Daly, MD, is being recognized by Continental Who's Who as a Trusted Healthcare Professional in the Medical field, acknowledging her exemplary work with Fairview Health Services.
  • Board-certified and fellowship-trained, Dr. Daly is a child psychiatrist at Fairview Health Services, where she has been in practice for 11 years.
  • Headquartered in Minneapolis, Fairview is "the health service that heals from the heart" and proudly serves as Minnesota's choice for healthcare.
  • Its broad network is designed to be ready for each patient's needs while delivering compassionate quality care.

Enveda Biosciences appoints industry leader Mark Deeg, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Tuesday, October 25, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Data Management, Technology, Pharmacology, Kidney, RNA transfection, Therapy, University of Minnesota Medical School, IND, Lilly, Machine learning, Proteolysis targeting chimera, Metabolomics, Biotechnology, List of life sciences, Research, Multimedia, Eli Lilly and Company, Technology, Knowledge, University, Goal, Drug discovery, Industry, CEO, Pain, Eli Lilly, Chemistry, Clinical trial, Leadership, Pharmaceutical industry, Management, Medical device

Enveda Biosciences today announced the appointment of Mark Deeg, M.D., Ph.D., as the companys Chief Medical Officer.

Key Points: 
  • Enveda Biosciences today announced the appointment of Mark Deeg, M.D., Ph.D., as the companys Chief Medical Officer.
  • View the full release here: https://www.businesswire.com/news/home/20221025006040/en/
    Enveda Biosciences today announced the appointment of industry leader Mark Deeg, M.D., Ph.D., as the company's Chief Medical Officer.
  • (Photo: Business Wire)
    We are thrilled to welcome Mark Deeg to Enveda as our Chief Medical Officer, said Viswa Colluru, Ph.D., founder and CEO of Enveda.
  • Prior to this tenure at Cullgen, Mark held positions in medical and research leadership in companies focused on digital and mRNA therapies.

Expert Panel Calls for Use of Blood Volume Measurement to Assess Heart Failure Patients at Key Scientific Meeting

Retrieved on: 
Wednesday, October 5, 2022
University of Texas Southwestern Medical Center, Pressure, Adoption, U.S. Department of Defense Strategy for Operating in Cyberspace, Method, Risk, Mayo Clinic, SEC, Growth, Duke University Health System, Patient, Critical care, Hospital, Research, NIH, Mortality, Device, Private Securities Litigation Reform Act, University of Minnesota Medical School, BVA, CEO, Heart failure, Volume overload, GLOBE, Forward-looking statement, University, FDA, COVID-19, Blood volume, Medical device, Pharmaceutical industry

Oak Ridge, TN, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that a scientific session titled “Debating Volume-based versus Pressure-based Methods and Devices to Measure Congestion in Heart Failure” was held during the Heart Failure Society of America Annual Scientific Meeting on October 3rd, 2022, in Washington, DC.

Key Points: 
  • In a debate format before hundreds of clinicians both on-line and in-person, the panel compared pressure-based vs volume-based measures to assess volume overload in advanced heart failure patients.
  • The panel unanimously agreed that pressure and volume do not give the same clinical information.
  • Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation.
  • We developed and market the BVA-100 (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms.

The Society To Improve Diagnosis In Medicine (SIDM) Reveals Full Speaker Line Up for SIDM2022

Retrieved on: 
Thursday, September 29, 2022
Safety, Movement, Center, SIDM, Health equity, Patient, Physician, Technology, FAAD, Blue, Minnesota State University, Mankato, Leadership, Racism, Human, Research, Public health, Coalition, MPH, MSW, Nursing, Assistant, Role, Division, Award, University of Minnesota Medical School, COVID, Student, MI, LICSW, Diagnosis, Associate, School, Equity, Society, Institute, Social work, Canadian Foundation for Healthcare Improvement, MD, Faculty, Partnership, Bill, CEO, Mankato, Minnesota, Health policy, Delays, Science, Government, Weill Cornell Medicine, Program, Solution, Bill & Melinda Gates Foundation, Awareness, Multimedia, University, AI, IHI, Wayne State University School of Medicine, Medical device, Management, Medicine, Medicine, Dermatology, Doctor of Philosophy, Health

ALPHARETTA, Ga., Sept. 29, 2022 /PRNewswire/ -- The Society to Improve Diagnosis in Medicine (SIDM), revealed today the final line up for SIDM2022, an annual national conference gathering of diverse, dynamic, and leading voices in the movement to improve medical diagnosis.

Key Points: 
  • ALPHARETTA, Ga., Sept. 29, 2022 /PRNewswire/ -- The Society to Improve Diagnosis in Medicine (SIDM), revealed today the final line up for SIDM2022, an annual national conference gathering of diverse, dynamic, and leading voices in the movement to improve medical diagnosis.
  • He is a physician scientist and is passionate about leveraging technology to improve health care for all.
  • The Society to Improve Diagnosis in Medicine (SIDM) catalyzes and leads change to improve diagnosis and eliminate harm from diagnostic error.We work in partnership with patients, their families, the healthcare community, and every interested stakeholder.
  • In 2015, SIDM established theCoalition to Improve Diagnosis to increase awareness and actions that improve diagnosis.

Parsemus Foundation: Common and Affordable Drug Can Drastically Reduce COVID Complications, Study Shows

Retrieved on: 
Tuesday, August 30, 2022
Research, Infectious Diseases, Diabetes, Clinical Trials, Philanthropy, Biotechnology, Pharmaceutical, Health, Foundation, Science, University, COVID-19, Metformin, Hospital, Parsemus Foundation, Ivermectin, Immunity, Vaccine, Solution, Death, University of Minnesota Medical School, Pregnancy, Internal medicine, Pediatrics, MD, The New England Journal of Medicine, Risk, COVID, Patient, Pharmaceutical industry

The multi-site COVID-OUT study compared three medications that have been considered promisinglow-dose fluvoxamine, an antidepressant; ivermectin, an antiparasitic drug; and metformin, a low-cost diabetes drug.

Key Points: 
  • The multi-site COVID-OUT study compared three medications that have been considered promisinglow-dose fluvoxamine, an antidepressant; ivermectin, an antiparasitic drug; and metformin, a low-cost diabetes drug.
  • Metformin reduced severe outcomes (hospitalization, emergency room visits, and death) by 42% or 55% if started within 4 days of symptoms.
  • The study included 1,323 individuals over 30 years old at elevated risk of severe outcomes.
  • This would be the first universally available treatment for COVID, giving lower-income countries a tool to combat the disproportionate impact of this disease.

Everlywell Launches Sexual Health Report Detailing How Navigating a Pandemic - and Now Epidemic - Have Changed our Sex Lives

Retrieved on: 
Thursday, August 4, 2022
Teens, Women, Infectious Diseases, Men, Telemedicine, Virtual Medicine, Lifestyle, Health, Consumer, General Health, Well, COVID-19, Vertically transmitted infection, Woman, Prevalence, SOS, Education, STI, MPH, HPV, STD, Health minister, Condom, Cancer, Institute, News, Infertility, Health, Recycling, Infection, COVID, CDC, Privacy, Risk, University, Partner (business rank), University of Minnesota Medical School, Chlamydia, Gonorrhea, Pharmaceutical industry, Birth control, Doctor of Philosophy

Americans have found themselves in a uniquely challenging position of navigating an STI epidemic and the COVID-19 pandemic all at once, said Dr. Liz Kwo, Chief Medical Officer of Everly Health.

Key Points: 
  • Americans have found themselves in a uniquely challenging position of navigating an STI epidemic and the COVID-19 pandemic all at once, said Dr. Liz Kwo, Chief Medical Officer of Everly Health.
  • Fortunately, Everlywells State of Sex (SOS) report found that young people are no longer afraid to talk about STIs.
  • Everlywell offers a full suite of diagnostic sexual health tests which pair at-home collection with certified laboratory processing.
  • Everlywells sexual health tests offer a convenient, discreet, transparently priced alternative to in-clinic visits and tests conducted in doctors offices.

SynerFuse™ Announces Fifth Patient Implanted in Integrated Spinal Fusion and DRG Neuromodulation Proof-of-Concept Study

Retrieved on: 
Tuesday, July 26, 2022
Patient, Back pain, Neuropathic pain, University, Spinal fusion, Doctor of Philosophy, M Health Fairview University of Minnesota Medical Center, CEO, Incidence, University of Minnesota Medical School, DRG, Safety, Multimedia, Quality of life, Spine, Failed back syndrome, Heart, Data monitoring committee, Dentistry, MD

MINNEAPOLIS, July 26, 2022 /PRNewswire/ -- Justin Zenanko, CEO of SynerFuse, Inc., a Minneapolis-based medical device company, is pleased to announce completion last week of the company's groundbreaking procedure in a fifth patient in the company's proof-of-concept study. The patients have been implanted by Michael C. Park, MD, PhD, and Rohan Lall, MD, at M Health Fairview University of Minnesota Medical Center. (See photo taken after the fifth surgery, left to right: Park, Lall, Zenanko, and SynerFuse Co-Founder and Chief Scientific Officer Greg Molnar, Ph.D.).

Key Points: 
  • The implantation of the fifth patient in our proof-of-concept study is an important milestone for SynerFuse.
  • "The implantation of the fifth patient in our proof-of-concept study is an important milestone for SynerFuse," said Zenanko.
  • We're one step closer to demonstrating the viability of our non-narcotic solution for spinal fusion patients with chronic lower back pain."
  • With 500,000 procedures performed annually, spinal fusion remains a common treatment for spinal instability, albeit with a high incidence of residual neuropathic pain.

Dennis Ohlrogge, MD, is being recognized by Continental Who's Who

Retrieved on: 
Thursday, July 21, 2022
Saint Mary's Hospital, University, Family medicine, Medicine, American Board of Family Medicine, University of Minnesota Medical School, Retirement, Continental, American Board of Commissioners for Foreign Missions, Mayo Clinic Health System, Mary, mother of Jesus, Cancer, Hospital, MD, Patient, Golf, Medical degree, Saint Clare

A seasoned, board-certified physician, Dr. Ohlrogge began his illustrious career in medicine in 1982.

Key Points: 
  • A seasoned, board-certified physician, Dr. Ohlrogge began his illustrious career in medicine in 1982.
  • The doctor specialized in providing comprehensive medical treatment and preventative care to people of all ages during his career.
  • In pursuit of his career, Dr. Ohlrogge earned his Medical Degree from the University of Minnesota Medical School in 1979.
  • In his free time, Dr. Ohlrogge enjoys playing golf and spending time with his 28-year-old son.

The Crutchfield Dermatology Foundation awards the Mel Reeves Memorial Scholarship to Walter Cortina Martinez at the High School for Recording Arts

Retrieved on: 
Thursday, June 30, 2022
Black Enterprise, Review, Master's degree, Journal, Minnesota Twins, Student National Medical Association, Poverty, Attention, Hellraiser, Student, Genomics, University, Secondary school, COVID-19, Private practice, University of Minnesota Medical School, High School for Recording Arts, Minnesota Association of Professional Employees, Clinical professor, Nursing, Carleton College, Violence, Minneapolis–Saint Paul, Mayo Clinic, Richard Barker (life sciences and healthcare leader), Record (newspaper), Douglas Black (physician), Le Cordon Bleu College of Culinary Arts Minneapolis/St. Paul, Wild, Executive, Medical school, Molecular biology, Physician, MD, Education, Management, Medicine, Lynx, Biology, Dermatology

EAGAN, Minn., June 30, 2022 /PRNewswire-PRWeb/ -- "We lost a champion 'for all that's right' this year. I would typically tell a family member, "I am sorry for your loss, but in Mel's case, I would honestly say I am sorry for our loss. He was a friend and a patient (with permission), and one of the last things he told me was that he wanted me to publish an article on Covid and the importance of getting vaccinated. He was unable to get vaccinated, and it was now too late. With labored breathing from his hospital bed, he suggested that my son, Charles IV, interview me on the topic. As an editor of the Spokesman-Recorder newspaper, he told me that he would edit, review, and publish it within an hour of receiving it. Mel did not make it, but the important article, and one of Mel's last assignments, was published. It was typical Mel, always looking out for others and anyone who might need help. That is why we developed the Mel Reeves Memorial Scholarship for students at the High School for Recording Arts in St. Paul, MN. to continue to follow the path the Mel had blazed." commented Charles E. Crutchfield III, MD

Key Points: 
  • That is why we developed the Mel Reeves Memorial Scholarship for students at the High School for Recording Arts in St. Paul, MN.
  • When Tony Simmons, the Executive Director of the High School for Recording Arts, informed me that Dr. Crutchfield and the Crutchfield Dermatology Foundation were developing a Mel Reeves Memorial Scholarship, I immediately thought of the senior student Walter Cortina Martinez.
  • "When I was told I had been nominated for Mel Reeves Memorial Scholarship, I started learning about Mr. Mel Reeves.
  • I am humbled and honored to receive the Mel Reeves Memorial Scholarship, " Walter Cortina Martinez commented.